HROW
Harrow, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
29.99
close · 2026-10-29
value
16
cheaper than peers16
quality
2
stronger fundamentals2
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 10.82× | 52 |
| EV to EBITDA | 44.04× | 24 |
| price to sales | 5.65× | 23 |
| price to book | 73.87× | 7 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -35.4% | 25 |
| revenue growth | -7.6% | 23 |
| operating margin | -50.0% | 9 |
| debt to equity | 1060.5% | 7 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$5.0M |
| employees | 373 |
| first trade | 2007-09-28 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.14 | -0.49 | -0.75 | -0.51 |
| free cash flow | $42.8M | -$60.9M | -$148.7M | -$6.1M |
| net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M |
| revenue | $272.3M | $199.6M | $130.2M | $88.6M |
| unusual items | -$7.8M | -$3.4M | -$2.8M | $2.3M |